Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apthera Inc.

This article was originally published in Start Up

Executive Summary

Apthera was formed two years ago to further develop NeuVax, an investigational therapeutic cancer vaccine. NeuVax, which combines the T-cell peptide E75 with GM-CSF, is poised to enter Phase III testing in early-stage breast cancer patients to prevent recurrence of the disease and is also in early trials in prostate cancer,

You may also be interested in...



RXi Acquires Apthera, Reorganizes To Support Late-Stage Breast Cancer Product

Formerly focused on preclinical RNA interference compounds, the company installs a new CEO and takes possession of a cancer immunotherapy, the latest move away from RNAi by companies big and small.

RXi Acquires Apthera, Reorganizes To Support Late-Stage Breast Cancer Product

Formerly focused on preclinical RNA interference compounds, the company installs a new CEO and takes possession of a cancer immunotherapy, the latest move away from RNAi by companies big and small.

Amping Up Dendritic Cells

Researchers are looking for ways to better stimulate dendritic cells (DCs, the antigen presenting cells that initiate and control many aspects of the immune response) in the hopes of creating potent vaccines against tumors and infectious diseases. A recent paper highlights progress on the DC targeting front using a DNA vaccine strategy, but is also a reminder that the immunotherapy field has a long way to go.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel